TY  - JOUR
AU  - Simoes, Fabio A
AU  - Joilin, Greig
AU  - Peters, Oliver
AU  - Schneider, Luisa-Sophie
AU  - Priller, Josef
AU  - Spruth, Eike Jakob
AU  - Vogt, Ina Rosemarie
AU  - Kimmich, Okka
AU  - Spottke, Annika
AU  - Hoffmann, Daniel C
AU  - Falkenburger, Björn
AU  - Brandt, Moritz
AU  - Prudlo, Johannes
AU  - Brockmann, Kathrin
AU  - Fries, Franca Laura
AU  - Rowe, James B
AU  - Church, Alistair
AU  - Respondek, Gesine
AU  - Newbury, Sarah F
AU  - Leigh, P Nigel
AU  - Morris, Huw R
AU  - Höglinger, Günter
AU  - Hafezparast, Majid
TI  - Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy.
JO  - International journal of molecular sciences
VL  - 23
IS  - 23
SN  - 1422-0067
CY  - Basel
PB  - Molecular Diversity Preservation International
M1  - DZNE-2023-00021
SP  - 14554
PY  - 2022
AB  - Objective markers for the neurodegenerative disorder progressive supranuclear palsy (PSP) are needed to provide a timely diagnosis with greater certainty. Non-coding RNA (ncRNA), including microRNA, piwi-interacting RNA, and transfer RNA, are good candidate markers in other neurodegenerative diseases, but have not been investigated in PSP. Therefore, as proof of principle, we sought to identify whether they were dysregulated in matched serum and cerebrospinal fluid (CSF) samples of patients with PSP. Small RNA-seq was undertaken on serum and CSF samples from healthy controls (n = 20) and patients with PSP (n = 31) in two cohorts, with reverse transcription-quantitative PCR (RT-qPCR) to confirm their dysregulation. Using RT-qPCR, we found in serum significant down-regulation in hsa-miR-92a-3p, hsa-miR-626, hsa-piR-31068, and tRNA-ValCAC. In CSF, both hsa-let-7a-5p and hsa-piR-31068 showed significant up-regulation, consistent with their changes observed in the RNA-seq results. Interestingly, we saw no correlation in the expression of hsa-piR-31068 within our matched serum and CSF samples, suggesting there is no common dysregulatory mechanism between the two biofluids. While these changes were in a small cohort of samples, we have provided novel evidence that ncRNA in biofluids could be possible diagnostic biomarkers for PSP and further work will help to expand this potential.
KW  - Humans
KW  - Supranuclear Palsy, Progressive: diagnosis
KW  - Supranuclear Palsy, Progressive: genetics
KW  - Biomarkers
KW  - MicroRNAs: genetics
KW  - Down-Regulation
KW  - PSP (Other)
KW  - RNA-seq (Other)
KW  - biomarker (Other)
KW  - non-coding RNA (Other)
KW  - progressive supranuclear palsy (Other)
KW  - Biomarkers (NLM Chemicals)
KW  - MicroRNAs (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:36498882
C2  - pmc:PMC9738832
DO  - DOI:10.3390/ijms232314554
UR  - https://pub.dzne.de/record/169142
ER  -